Phibro Animal Health (NASDAQ:PAHC) CEO Sells $552,372.84 in Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 13,158 shares of Phibro Animal Health stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $41.98, for a total value of $552,372.84. Following the transaction, the chief executive officer directly owned 18 shares in the company, valued at approximately $755.64. The trade was a 99.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jack Bendheim also recently made the following trade(s):

• On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.68, for a total transaction of $612,154.16.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.02, for a total transaction of $117,338.64.
• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.53, for a total transaction of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.32, for a total transaction of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.16, for a total transaction of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.09, for a total transaction of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.93, for a total transaction of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.19, for a total value of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.06, for a total value of $141,011.20.
• On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.77, for a total value of $143,510.40.

Phibro Animal Health Stock Performance

Shares of NASDAQ PAHC opened at $39.01 on Friday. The stock’s fifty day simple moving average is $40.16 and its 200 day simple moving average is $37.52. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 1.10 and a beta of 0.79. The company has a quick ratio of 1.35, a current ratio of 3.09 and a debt-to-equity ratio of 2.32. Phibro Animal Health Corporation has a 52-week low of $16.16 and a 52-week high of $46.42.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.15. The business had revenue of $363.89 million during the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. As a group, sell-side analysts forecast that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th were given a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend was Wednesday, November 26th. Phibro Animal Health’s dividend payout ratio (DPR) is 28.92%.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors have recently modified their holdings of PAHC. Farther Finance Advisors LLC grew its holdings in shares of Phibro Animal Health by 113.2% during the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after acquiring an additional 386 shares in the last quarter. Financial Management Professionals Inc. purchased a new stake in shares of Phibro Animal Health during the second quarter worth $32,000. Hughes Financial Services LLC acquired a new stake in Phibro Animal Health during the third quarter valued at $40,000. iSAM Funds UK Ltd acquired a new stake in Phibro Animal Health during the third quarter valued at $61,000. Finally, EverSource Wealth Advisors LLC grew its stake in Phibro Animal Health by 7,671.4% in the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock valued at $69,000 after purchasing an additional 2,685 shares in the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 9th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Finally, JPMorgan Chase & Co. lifted their price target on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Phibro Animal Health has a consensus rating of “Hold” and an average target price of $31.40.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.